| Bid | 17.15 |
| Market Cap | 1.33B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -153.17 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 29.34 |
| Volume | 294,365 |
| Avg. Volume (20D) | 346,308 |
| Open | 18.33 |
| Previous Close | 18.17 |
| Day's Range | 18.22 - 18.92 |
| 52-Week Range | 16.56 - 28.15 |
| Beta | undefined |
About KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...
Analyst Forecast
According to 5 analyst ratings, the average rating for KNSA stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 90.42% from the latest price.
Next Earnings Release
Analysts project revenue of $123.31M, reflecting a 47.86% YoY growth and earnings per share of 0.13, making a -62.86% decrease YoY.
2 months ago · seekingalpha.com
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call TranscriptKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chair...
